»
SECTION TITLE
» P.I.N. Pharmaceutical Patent Innovation News Article Title
Tara Innovations, LLC
www.tarainnovations.com *
hemantjoshi@tarainnovations.com
Points
The purpose of this column is to highlight and summarize recent key patents in the pharmaceutical arena issued by the US Patent Offi ce.
Harshada Sant, MS and Hemant N. Joshi, Ph.D., MBA*
Skin Whitening Composition Containing Chia Seed Extract.
J. Rana, G. Diwakar, and J. Scholten; US Patent # 8,916,212. December 23, 2014.
Introduction Paragrapgh Text
This topical composition includes an alcoholic extract of Salvia hispanica (Chia) seed in a glycol carrier in an amount effective for inhibiting melanin content in the skin. The composition may further include a permeation enhancer, such as dimethyl sulfoxide (DMSO) and a Punica granatum (Pomegranate) extract. Melanin is formed via a process termed melanogenesis. In order to lighten the tone of the skin, it is necessary to reduce or inhibit melanogenesis. Seed extracts are known to carry or store a rich variety of medicinally beneficial bioactive agents. The conventional chia seed oil preparations are known to contain high levels of alpha-linolenic acid and linoleic acid—2 fatty acids known to suppress melanin production.
Temperature-controlled and pH-dependent Self-gelling
Author Name
Author Title Author Company
Biopolymeric Aqueous Solution.
A. Chenite, C. Chaput, D. Wang, and A. Selmani; US Patent # 8,920,842. December 30, 2014.
The invention describes a polymeric self-gelling
composition that remains liquid at temperatures of 4°C to 15°C and solidifi es when heated to 30°C to 60°C. It has a new gelation mechanism that combines hydrogen bonding, electrostatic interactions, and hydrophilic/hydrophobic interactions. The composition contains an acid soluble (pH 1 to 5) biopolymer (chitosan or its derivatives, ie, collagenous proteins), water soluble biopolymer in the pH range 6.5 to 7.4 (cellulosic polymers, polyvinyl alcohol), and admixed molecules (organic salts and amino acids). The admixed molecule is required to play a double role in increasing the pH within the biopolymeric solution up to physiological conditions (~pH 7.4) and preventing the immediate gelation or aggregation.
Injectable Flowable Composition Comprising
Buprenorphine.
R. L. Norton, A. Watkins, and M. Zhou; US Patent # 8,921,387. December 30, 2014.
This buprenorphine delivery system includes a fl owable composition which is transformed to a solid implant in situ by contact with water or body fl uid for the sustained release of buprenorphine for approximately 14 days to 3 months. Buprenorphine is available as tablets (buccal/ sublingual) intended to deliver the drug for short periods of time. A need exists to supplement this dose at regular intervals, but this can be challenging for patient with an opiod dependence problem. The mentioned delivery system includes a fl owable composition comprising of a biodegradable thermoplastic polymer, a biocompatible, polar organic liquid, and buprenorphine.
66 |
| November/December 2011 January/February 2015
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76